Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal

Acadia Pharma’s primary strategy over the last few years has been to get its controversial Parkinson’s drug approved for other diseases, including depression and schizophrenia. Now, for the first time in 2 years, the company is adding a new chemical to its pipeline.